Supplementary Table S7 from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
crossref（2024）
摘要
Treatment-emergent SAEs (MedDRA preferred terms; incidence ≥1%)
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要